What is Cytomel?
Cytomel (liothyronine sodium) is a synthetic form of the thyroid hormone T3 (triiodothyronine) that is FDA-approved for treating hypothyroidism, but current clinical guidelines strongly recommend against its routine use in favor of levothyroxine (T4) monotherapy. 1
Pharmacological Description
Cytomel contains liothyronine sodium, a synthetic preparation of L-triiodothyronine (T3), one of the two main thyroid hormones naturally produced by the thyroid gland 1. The drug is available in tablets of 5 mcg, 25 mcg, and 50 mcg strengths. Approximately 25 mcg of liothyronine is equivalent to 1 grain of desiccated thyroid or 0.1 mg of levothyroxine 1.
FDA-Approved Indications
According to the FDA label, Cytomel is indicated for 1:
- Replacement therapy in hypothyroidism of any etiology (primary, secondary, or tertiary)
- TSH suppression in euthyroid goiters, thyroid nodules, and chronic lymphocytic thyroiditis
- Diagnostic testing for thyroid gland autonomy
- Patients with allergies to desiccated thyroid preparations
Clinical Guideline Position
Despite FDA approval, major endocrinology guidelines explicitly recommend against using liothyronine-containing preparations for routine hypothyroidism treatment. The 2012 AACE/ATA guidelines state there is no evidence supporting desiccated thyroid hormone or T3/T4 combinations over levothyroxine monotherapy (Grade D recommendation) 2.
Key Guideline Restrictions:
- L-thyroxine and L-triiodothyronine combinations should NOT be administered to pregnant women or those planning pregnancy (Grade B) 2
- Desiccated thyroid hormone should not be used for hypothyroidism treatment 2
- TRIAC (tiratricol) should not be used for primary or central hypothyroidism 2
Safety Concerns
Recent evidence reveals significant cardiovascular risks with liothyronine use:
A 2022 propensity-matched study found LT3 users had 66% higher risk of heart failure (IRR=1.664) and 76% higher risk of stroke (IRR=1.757) compared to levothyroxine-only users 3. These risks were particularly elevated in:
- Patients with thyroid cancer history
- Those using LT3 for ≥52 weeks
The elderly are especially vulnerable to atrial fibrillation with overtreatment, and postmenopausal women face accelerated bone loss 2.
Limited Clinical Scenarios for Consideration
While guidelines discourage routine use, a 2023 British consensus statement suggests a trial of combination therapy may be warranted only after 4:
- Confirming overt hypothyroidism (not subclinical)
- Optimizing levothyroxine to achieve TSH 0.3-2.0 mIU/L for 3-6 months
- Excluding other comorbidities causing persistent symptoms
- Shared decision-making with the patient
However, a 2025 observational study suggested 16-31% lower dementia and mortality risks with combination therapy versus levothyroxine alone, though this requires confirmation in randomized trials 5.
Critical Clinical Pitfall
Liothyronine can precipitate adrenal crisis in patients with undiagnosed adrenal insufficiency. A case report documented a patient whose fatigue and dizziness worsened after starting Cytomel, revealing underlying Addison's disease 6. Patients with adrenal insufficiency must receive hydrocortisone before initiating thyroid hormone replacement 2.
Bottom Line
Cytomel is a potent T3 preparation that, despite FDA approval, should not be used routinely for hypothyroidism. Levothyroxine monotherapy remains the standard of care, with combination therapy reserved only for highly selected patients who fail optimized levothyroxine treatment after thorough evaluation and shared decision-making.